Author

Jenesse Nicole Moffett

Observed names: J Nicole Moffett, J. Nicole Moffett, J.N. Moffett, Jenesse N. Moffett, Nicole Moffett

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)

ORCID: 0000-0003-2331-8153

Observed ORCID: 0000-0003-2331-8153

OpenAlex ID: A5075458388

Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab

2022 · Robert W. Gao, Courtney N. Day, et al. · Lung Cancer · 30

Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report

2023 · Aakash Desai, Sagar Rakshit, et al. · Cancer Treatment and Research Communications · 23

Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer

2023 · Aakash Desai, Caleb J. Smith, et al. · Clinical Lung Cancer · 21

MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.

2022 · Konstantinos Leventakos, Anastasios Dimou, et al. · Journal of Clinical Oncology · 4

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

2025 · Aditi Singh, Arthi Sridhar, et al. · JTO Clinical and Research Reports · 2

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

2025 · Richard T. Roden, William S. Harmsen, et al. · Lung Cancer · 1

Unusual outcome of treatment of thymoma with immunotherapy: case report

2024 · Mohamed Shanshal, Joseph Maakaron, et al. · Mediastinum · 1

Single institution toxicity of definitive chemoradiation and maintenance durvalumab in locally advanced non-small cell lung cancer.

2021 · Pranitha Prodduturvar, Konstantinos Leventakos, et al. · Journal of Clinical Oncology · 1

MC1923: Phase II durvalumab plus lurbinectedin in platinum-resistant relapsed extensive-stage small cell lung cancer after prior chemoimmunotherapy (cohort B).

2026 · Konstantinos Leventakos, Anastasios Dimou, et al. · Journal of Clinical Oncology

P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

2024 · A. Sridhar, A. Schwecke, et al. · Journal of Thoracic Oncology

PP01.108 Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial

2024 · Mariana Borras Osorio, Megan E. Branda, et al. · Journal of Thoracic Oncology

Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC).

2024 · Arthi Sridhar, Aditi Singh, et al. · Journal of Clinical Oncology

EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma

2023 · C.J. Smith, A. Desai, et al. · Journal of Thoracic Oncology

EP05.01-011 Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience

2022 · J. Rivera Concepcion, P. Prodduturvar, et al. · Journal of Thoracic Oncology

Works count: 14

Citation count: 83

H-index: 4

I10-index: 3